global glp-1 obesity drug market size forecast 2030 Drugs to Hit USD 132.79 Bn by 2035 GLP-1 Weight-Loss Drugs Ride Health,

H.RennenburgH

Bibcode:1987PNAS...84.2377B

Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats

CagriSema, a subcutaneous combination of semaglutide and a novel amylin analogue, cagrilintide, is administered once weekly in patients with type 2 diabetes and overweight Novo Nordisk In April 2022, phase 3 clinical trial to evaluate the efficacy and safety of tirzepatide in adults with obesity or overweight and at least one comorbidity apart from diabetes, delivered up to 22.5% weight loss Eli Lilly and Company's In January 2022, the has cleared Altimmune, Inc.s Investigational New Drug (IND) application for the Phase 2 clinical trial of pemvidutide, an investigational GLP-1/glucagon dual receptor agonist under development, indicated for the treatment of obesity and non-alcoholic steatohepatitis (NASH)